FDA Panel to Review Grail’s Multi-Cancer Blood Test
On September 23, when an independent panel of experts convenes to evaluate the premarket approval application for Grail’s Galleri multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel’s upcoming vote marks a major regulatory milestone for liquid biopsy technology, though the agency is not legally bound to follow the committee’s non-binding recommendation.
The Regulatory Landscape and Premarket Approval Stakes
Grail submitted its premarket approval application in late January, setting the stage for what is the first multi-cancer early detection blood test to reach a full advisory committee review in the United States, according to Medical Daily. Currently, the test is sold across the U.S. as a prescription-only laboratory test. Federal approval would fundamentally shift its regulatory status rather than introduce an entirely new market entrant.
Examining the Clinical Data Behind the Vote
The core question before the committee narrows down to test performance metrics rather than long-term mortality benefits. According to data drawn from 25,490 consented participants in the U.S.-based PATHFINDER 2 study alongside figures from over 70,000 participants in the UK’s NHS-Galleri trial, the test demonstrates high specificity at 99.6%, keeping the false positive rate below 0.4%. Furthermore, the full PATHFINDER 2 results presented at ASCO showed a positive predictive value of 60.3%, indicating that roughly three in five individuals with a positive result were confirmed to have cancer.
However, sensitivity metrics present a more complex picture for the committee to weigh. Across all cancers, episode sensitivity—defined as the ability to detect cancer confirmed within 12 months of the blood draw—stood at 39.3%. For the 12 specific cancers responsible for two-thirds of U.S. cancer deaths, sensitivity rose to 69.8%. Grail reported that adding Galleri to recommended screenings increased screen-detected cancers by up to 6.5-fold, with 70.9% of those newly detected cases falling between stages I through III.
Weighing Screening Standards and Behavioral Risks
Screening tests face a distinctly different evaluative hurdle than standard diagnostic tools. As noted in historical screening data analyses, a test can successfully identify cancers earlier without automatically guaranteeing a reduction in overall mortality, given that some detected malignancies might never progress to cause harm. The PATHFINDER 2 study is a single-arm interventional trial measuring test performance rather than tracking comparative outcomes against an unscreened cohort.
Because a negative blood test does not rule out cancer, the test is strictly intended to supplement—not replace—established screening protocols like mammograms, colonoscopies, cervical screenings, and lung computed tomography. If patients misinterpret a negative blood test as absolute clearance and forgo routine guideline-recommended screenings, the overall public health impact could turn counterproductive.
Comparative Regulatory Milestones in Diagnostics
Leerink Partners analyst Puneet Souda noted that the Shield approval helped target millions of unscreened individuals. While Shield demonstrated an 83% sensitivity rate for colorectal cancers, fecal-based alternatives like Cologuard recorded a 92.3% sensitivity rate, with colonoscopy remaining the clinical gold standard.
As the Molecular and Clinical Genetics Panel prepares to cast its vote, stakeholders across the healthcare and corporate sectors watch to see how federal regulators interpret complex sensitivity data against a backdrop of urgent unmet medical needs.
Disclaimer: The views and cultural analyses presented in this article are for informational and entertainment purposes only. Information regarding legal disputes or financial data is based on available public records.